Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan;
Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Anticancer Res. 2022 Oct;42(10):4907-4912. doi: 10.21873/anticanres.15996.
BACKGROUND/AIM: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive R/M HNSCC has not been shown. Therefore, this study compared the efficacy and safety of nivolumab for platinum-refractory and platinum-sensitive R/M HNSCC.
This was a retrospective study of patients who received nivolumab for R/M HNSCC who had been previously treated with platinum-based anticancer drugs. Patients were divided into a platinum-sensitive and a platinum-refractory group, and progression-free survival (PFS), overall survival (OS), the overall response rate (ORR) [complete response (CR) + partial response (PR)], the disease control rate (DCR) (CR + PR + stable disease), and the incidence of immune-related adverse events (irAEs) were compared between the two groups.
We included 88 patients with squamous cell carcinoma: 60 with platinum-refractory disease and 28 with platinum-sensitive disease. The median PFS in the platinum-refractory and platinum-sensitive groups were 2.7 months and 5.3 months, respectively (p=0.03), and the median OS were 8.8 months and 17.1 months, respectively (p=0.06). There were no significant differences in the ORR, DCR, or incidence of irAEs between the two groups (p>0.99, p=0.11, and p>0.99, respectively).
Nivolumab is a safe and effective treatment for platinum-sensitive R/M HNSCC.
背景/目的：纳武利尤单抗在铂类治疗后 6 个月内复发/转移性头颈部鳞状细胞癌（R/M HNSCC）患者中具有抗肿瘤疗效；然而，纳武利尤单抗在铂类敏感的 R/M HNSCC 中的疗效尚未得到证实。因此，本研究比较了纳武利尤单抗治疗铂类耐药和铂类敏感的 R/M HNSCC 的疗效和安全性。
这是一项回顾性研究，纳入了先前接受过铂类抗癌药物治疗的 R/M HNSCC 患者接受纳武利尤单抗治疗。患者分为铂类敏感组和铂类耐药组，比较两组间无进展生存期（PFS）、总生存期（OS）、总缓解率（ORR）[完全缓解（CR）+部分缓解（PR）]、疾病控制率（DCR）（CR+PR+稳定疾病）和免疫相关不良事件（irAE）的发生率。
共纳入 88 例鳞状细胞癌患者：60 例铂类耐药，28 例铂类敏感。铂类耐药组和铂类敏感组的中位 PFS 分别为 2.7 个月和 5.3 个月（p=0.03），中位 OS 分别为 8.8 个月和 17.1 个月（p=0.06）。两组间 ORR、DCR 和 irAE 发生率无显著差异（p>0.99，p=0.11 和 p>0.99，分别）。
纳武利尤单抗是铂类敏感 R/M HNSCC 的一种安全有效的治疗方法。
